SCYX (SCYNEXIS, Inc.) Stock Financials & Earnings | Market Cap Arena

SCYX (SCYNEXIS, Inc.) Stock Financials & Earnings | Market Cap Arena

SCYXSCYNEXIS, Inc.

Mkt Cap$38M

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Revenue (TTM)$21M

Net Income (TTM)-$9M

EPS (TTM)-$0.14

Free Cash Flow (TTM)-$5M

Gross Margin9.5%

Op. Margin-77.9%

Net Margin-41.8%

FCF Margin-25.6%

P/S Ratio (TTM)1.9x

P/E Ratio (TTM)—

YoY Rev Growth+449.9%

Employees—

Earnings Reports

Next: Q1 2026 · Mar 11

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$1M	$993K	-$11M
Q2 23	$131M	$131M	$117M
Q3 23	$2M	$1M	-$10M
Q4 23	$6M	-$9M	-$23M
Q1 24	$1M	$1M	-$10M
Q2 24	$736K	$736K	-$9M
Q3 24	$660K	$660K	-$10M
Q4 24	$977K	$977K	-$8M
Q1 25	$257K	$257K	-$9M
Q2 25	$1M	$1M	-$10M
Q3 25	$334K	$334K	-$8M
Q4 25	$19M	$0	$11M

Valuation

Quarter	P/S	P/E
Q1 23	6.9x	—
Q2 23	0.3x	0.9x
Q3 23	0.3x	0.5x
Q4 23	0.3x	0.6x
Q1 24	0.3x	0.4x
Q2 24	3.9x	—
Q3 24	4.5x	—
Q4 24	10.2x	—
Q1 25	14.5x	—
Q2 25	11.7x	—
Q3 25	13.0x	—
Q4 25	1.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$19M	-$19M
Q2 23	$74M	$74M
Q3 23	$12M	$12M
Q4 23	-$8M	-$8M
Q1 24	-$4M	$0
Q2 24	-$11M	-$11M
Q3 24	$765K	$765K
Q4 24	-$10M	-$10M
Q1 25	-$7M	-$7M
Q2 25	-$7M	-$7M
Q3 25	-$9M	-$9M
Q4 25	$18M	$18M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$4M
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+64.5%	-42.2%
Q2 23	+9836.1%	-35.2%
Q3 23	+13.1%	-49.2%
Q4 23	+280.4%	+20.2%
Q1 24	+21.5%	-7.9%
Q2 24	-99.4%	-33.2%
Q3 24	-62.5%	-7.4%
Q4 24	-83.1%	-68.7%
Q1 25	-81.3%	-18.5%
Q2 25	+85.3%	+9.5%
Q3 25	-49.4%	-20.4%
Q4 25	+1808.5%	-10.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$707K	62.6%
Q2 23	$728K	0.6%
Q3 23	$632K	35.9%
Q4 23	$557K	9.6%
Q1 24	$705K	51.3%
Q2 24	$759K	103.1%
Q3 24	$901K	136.5%
Q4 24	$981K	100.4%
Q1 25	$819K	318.7%
Q2 25	$820K	60.1%
Q3 25	$526K	157.5%
Q4 25	$687K	3.7%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$7M	$5M
Q2 23	$7M	$7M
Q3 23	$6M	$5M
Q4 23	$11M	$3M
Q1 24	$7M	$4M
Q2 24	$7M	$3M
Q3 24	$8M	$3M
Q4 24	$4M	$5M
Q1 25	$5M	$4M
Q2 25	$7M	$4M
Q3 25	$5M	$3M
Q4 25	$5M	$4M

Revenue Segments

Quarter	License and Service	Product
Q2 23	$131M	$468K
Q3 23	$2M	-$614K
Q1 24	$1M	—
Q2 24	$736K	—
Q3 24	$660K	—
Q1 25	$257K	—
Q2 25	$1M	—
Q3 25	$334K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$27M	$28M	$55M
Q2 23	$58M	$28M	$86M
Q3 23	$44M	$44M	$88M
Q4 23	$34M	$40M	$74M
Q1 24	$36M	$45M	$81M
Q2 24	$26M	$47M	$73M
Q3 24	$29M	$40M	$69M
Q4 24	$16M	$43M	$59M
Q1 25	$7M	$34M	$41M
Q2 25	$11M	$34M	$45M
Q3 25	$15M	$23M	$38M
Q4 25	$21M	$19M	$40M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	48M	+46.1%
Q2 23	50M	+4.5%
Q3 23	48M	-4.1%
Q4 23	48M	+0.1%
Q1 24	49M	+1.3%
Q2 24	49M	-0.1%
Q3 24	49M	+0.2%
Q4 24	38M	-21.9%
Q1 25	49M	+30.2%
Q2 25	50M	+0.6%
Q3 25	50M	+0.3%
Q4 25	44M	-12.7%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$14K	87
FY 15	$23K	11
FY 16	$18K	14
FY 17	$14K	19
FY 18	$11K	24
FY 19	$4K	27
FY 20	$0	38
FY 21	$235K	56
FY 22	$141K	36
FY 23	$5M	29
FY 24	$134K	28
FY 25	$1M	18